P442 Real-world endoscopic and histologic outcomes are linked to ustekinumab exposure in Ulcerative Colitis

Dahham Alsoud(KU Leuven), Bram Verstockt(Universitair Ziekenhuis Leuven), Séverine Vermeire(KU Leuven), Marc Ferrante(Universitair Ziekenhuis Leuven), Sophie Tops(KU Leuven), João Sabino(KU Leuven), Gert De Hertogh(KU Leuven), Griet Compernolle(KU Leuven), Debby Thomas(KU Leuven)

Journal of Crohn s and Colitis

January 1, 2022

10.1093/ecco-jcc/jjab232.569

Cited by 4

Related Papers

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

|Nature Genetics|2008|2.6k

A decrease of the butyrate-producing species <i>Roseburia hominis</i> and <i>Faecalibacterium prausnitzii</i> defines dysbiosis in patients with ulcerative colitis

|Gut|2013|1.9k

ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications

|Journal of Crohn s and Colitis|2018|1.8k

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

|New England Journal of Medicine|2016|1.8k

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

|Journal of Crohn s and Colitis|2019|1.4k